These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 1905593

  • 1. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.
    Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang SP, Tung JS, Mark GE.
    Circulation; 1991 Jul; 84(1):244-53. PubMed ID: 1905593
    [Abstract] [Full Text] [Related]

  • 2. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
    Mellott MJ, Stabilito II, Holahan MA, Cuca GC, Wang S, Li P, Barrett JS, Lynch JJ, Gardell SJ.
    Arterioscler Thromb; 1992 Feb; 12(2):212-21. PubMed ID: 1371932
    [Abstract] [Full Text] [Related]

  • 3. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR, Wu Z, Pauwels P, Lijnen HR, Collen D.
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
    Montoney M, Gardell SJ, Marder VJ.
    Circulation; 1995 Mar 01; 91(5):1540-4. PubMed ID: 7867196
    [Abstract] [Full Text] [Related]

  • 5. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model.
    Mellott MJ, Ramjit DR, Stabilito II, Hare TR, Senderak ET, Lynch JJ, Gardell SJ.
    Thromb Haemost; 1995 Mar 01; 73(3):478-83. PubMed ID: 7545321
    [Abstract] [Full Text] [Related]

  • 6. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ, Wu ZM, Stassen T, Van de Werf F, Collen D.
    Blood; 1990 Oct 15; 76(8):1558-63. PubMed ID: 2119830
    [Abstract] [Full Text] [Related]

  • 7. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF, Voytik S, Klabunde RE, Henkin J, Leski M.
    Thromb Res; 1988 Nov 15; 52(4):295-312. PubMed ID: 3144052
    [Abstract] [Full Text] [Related]

  • 8. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats.
    Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD.
    Blood; 1992 Mar 01; 79(5):1213-7. PubMed ID: 1536947
    [Abstract] [Full Text] [Related]

  • 9. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
    Weitz JI.
    J Vasc Interv Radiol; 1995 Mar 01; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
    [Abstract] [Full Text] [Related]

  • 10. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.
    Circulation; 1991 Sep 01; 84(3):1216-34. PubMed ID: 1909220
    [Abstract] [Full Text] [Related]

  • 11. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR, Timony GA, Horgan PG, Barone KM, Henson KS, Angus LB, Stoudemire JB.
    J Biol Chem; 1991 May 05; 266(13):8156-61. PubMed ID: 1708773
    [Abstract] [Full Text] [Related]

  • 12. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
    Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD.
    Circulation; 1994 Jul 05; 90(1):421-6. PubMed ID: 8026028
    [Abstract] [Full Text] [Related]

  • 13. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator.
    Gardell SJ, Hare TR, Bergum PW, Cuca GC, O'Neill-Palladino L, Zavodny SM.
    Blood; 1990 Dec 15; 76(12):2560-4. PubMed ID: 2124935
    [Abstract] [Full Text] [Related]

  • 14. Comparative time course of thrombolysis induced by intravenous boluses and infusion of staphylokinase and tissue plasminogen activator in a rabbit arterial thrombosis model.
    Helft G, Bara L, Bloch MF, Samama MM.
    Blood Coagul Fibrinolysis; 1998 Jul 15; 9(5):411-7. PubMed ID: 9712289
    [Abstract] [Full Text] [Related]

  • 15. Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model.
    Kornowski R, Chernine A, Hasdai D, Ovadia Z, Battler A.
    Eur Heart J; 1995 Feb 15; 16(2):177-83. PubMed ID: 7744088
    [Abstract] [Full Text] [Related]

  • 16. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D.
    Circ Res; 1990 Dec 15; 67(6):1552-61. PubMed ID: 2123135
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK, Schleuning WD.
    Thromb Haemost; 2004 Sep 15; 92(3):559-67. PubMed ID: 15351852
    [Abstract] [Full Text] [Related]

  • 20. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.